| 潘 毅,马吉安,邹 华,蒋清虎,黄 滔.复方苦参注射液联合TACE对中晚期肝癌患者预后、生存质量和血清AFP、AFP-L3水平的影响[J].现代生物医学进展英文版,2021,(23):4454-4457. |
| 复方苦参注射液联合TACE对中晚期肝癌患者预后、生存质量和血清AFP、AFP-L3水平的影响 |
| Effect of Compound Kushen Injection Combined with TACE on Prognosis, Quality of Life and Serum AFP, AFP-L3 Levels in Patients with Advanced Liver Cancer |
| Received:April 06, 2021 Revised:April 29, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.23.011 |
| 中文关键词: 复方苦参注射液 肝动脉化疗栓塞术 中晚期肝癌 预后 生存质量 甲胎蛋白 甲胎蛋白异质体 |
| 英文关键词: Compound Kushen injection Transcatheter arterial chemoembolization Advanced liver cancer Prognosis Quality of life Alpha fetoprotein Alpha fetoprotein heterogeneity |
| 基金项目:四川省科技厅重大专项基金资助项目（2019YFS0372） |
|
| Hits: 964 |
| Download times: 499 |
| 中文摘要: |
| 摘要 目的：观察肝动脉化疗栓塞术（TACE）联合复方苦参注射液对中晚期肝癌患者预后、生存质量和血清甲胎蛋白（AFP）、甲胎蛋白异质体（AFP-L3）水平的影响。方法：选择我院于2016年3月~2019年10月期间收治的98例中晚期肝癌患者，经随机数字表法分为对照组（49例，TACE治疗）和研究组（49例，复方苦参注射液联合TACE治疗）。对比两组疗效、生存率、生存质量改善率、血清AFP、AFP-L3水平及不良反应发生率。结果：与对照组比较，研究组的临床总有效率明显升高（P<0.05）。研究组的1年生存率高于对照组（P<0.05）。与对照组比较，研究组的生存质量改善率明显升高（P<0.05）。两组治疗后血清AFP、AFP-L3水平较治疗前下降，且研究组低于对照组（P<0.05）。两组不良反应总发生率组间对比无统计学差异（P>0.05）。结论：TACE基础上联合复方苦参注射液治疗中晚期肝癌患者，可改善其短期预后及生存质量，降低其血清AFP、AFP-L3水平。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of transcatheter arterial chemoembolization(TACE) combined with Compound Kushen injection on prognosis, quality of life and serum alpha fetoprotein (AFP) and alpha fetoprotein heterogeneity (AFP-L3) levels in patients with advanced liver cancer. Methods: 98 patients with advanced liver cancer who were treated in our hospital from March 2016 to October 2019 were selected. By random number table method, they were divided into control group (49 cases, TACE treatment) and study group (49 cases, Compound Kushen injection combined with TACE treatment). The curative effect, survival rate, quality of life improvement rate, serum AFP, AFP-L3 levels and adverse reactions rate were compared between the two groups. Results: Compared with the control group, the total clinical effective rate of the study group was significantly increased (P<0.05). The one-year survival rate of the study group was higher than that of the control group (P<0.05). Compared with the control group, the quality of life improvement rate of the study group was significantly increased (P<0.05). The serum AFP, AFP-L3 levels in the two groups were lower than those before treatment, and the study group was lower than the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Combined with Compound Kushen injection on the basis of TACE can improve the short-term prognosis and quality of life of patients with advanced liver cancer, and reduce the serum AFP and AFP-L3 levels. |
|
View Full Text
View/Add Comment Download reader |
| Close |
